vs
Side-by-side financial comparison of Atour Lifestyle Holdings Ltd (ATAT) and Royalty Pharma plc (RPRX). Click either name above to swap in a different company.
Atour Lifestyle Holdings Ltd is the larger business by last-quarter revenue ($789.6M vs $622.0M, roughly 1.3× Royalty Pharma plc). Royalty Pharma plc runs the higher net margin — 34.4% vs 17.6%, a 16.8% gap on every dollar of revenue. On growth, Atour Lifestyle Holdings Ltd posted the faster year-over-year revenue change (252.5% vs 4.8%).
Atour Lifestyle Holdings Ltd is a leading China-based hospitality and lifestyle enterprise. It operates a wide portfolio of mid-to-premium hotel brands for business and leisure travelers, and offers complementary lifestyle retail products and experience services, catering primarily to middle-class consumers across domestic and selected overseas markets.
Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.
ATAT vs RPRX — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $789.6M | $622.0M |
| Net Profit | $139.1M | $214.2M |
| Gross Margin | — | — |
| Operating Margin | 22.5% | 62.4% |
| Net Margin | 17.6% | 34.4% |
| Revenue YoY | 252.5% | 4.8% |
| Net Profit YoY | 322.2% | 2.9% |
| EPS (diluted) | $0.33 | $0.49 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $622.0M | ||
| Q3 25 | $789.6M | $609.3M | ||
| Q2 25 | — | $578.7M | ||
| Q1 25 | — | $568.2M | ||
| Q4 24 | — | $593.6M | ||
| Q3 24 | $224.0M | $564.7M | ||
| Q2 24 | — | $537.3M | ||
| Q1 24 | $203.4M | $568.0M |
| Q4 25 | — | $214.2M | ||
| Q3 25 | $139.1M | $288.2M | ||
| Q2 25 | — | $30.2M | ||
| Q1 25 | — | $238.3M | ||
| Q4 24 | — | $208.2M | ||
| Q3 24 | $33.0M | $544.0M | ||
| Q2 24 | — | $102.0M | ||
| Q1 24 | $35.6M | $4.8M |
| Q4 25 | — | 62.4% | ||
| Q3 25 | 22.5% | 70.1% | ||
| Q2 25 | — | 36.3% | ||
| Q1 25 | — | 94.0% | ||
| Q4 24 | — | 60.9% | ||
| Q3 24 | 14.7% | — | ||
| Q2 24 | — | 50.2% | ||
| Q1 24 | 22.1% | -13.0% |
| Q4 25 | — | 34.4% | ||
| Q3 25 | 17.6% | 47.3% | ||
| Q2 25 | — | 5.2% | ||
| Q1 25 | — | 41.9% | ||
| Q4 24 | — | 35.1% | ||
| Q3 24 | 14.7% | 96.3% | ||
| Q2 24 | — | 19.0% | ||
| Q1 24 | 17.5% | 0.8% |
| Q4 25 | — | $0.49 | ||
| Q3 25 | $0.33 | $0.67 | ||
| Q2 25 | — | $0.07 | ||
| Q1 25 | — | $0.55 | ||
| Q4 24 | — | $0.46 | ||
| Q3 24 | $0.08 | $1.21 | ||
| Q2 24 | — | $0.23 | ||
| Q1 24 | $0.09 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $669.2M | $618.7M |
| Total DebtLower is stronger | — | $9.0B |
| Stockholders' EquityBook value | $405.0M | $9.7B |
| Total Assets | $1.1B | $19.6B |
| Debt / EquityLower = less leverage | — | 0.92× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $618.7M | ||
| Q3 25 | $669.2M | $938.9M | ||
| Q2 25 | — | $631.9M | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | — | $929.0M | ||
| Q3 24 | $506.0M | $950.1M | ||
| Q2 24 | — | $1.8B | ||
| Q1 24 | $520.7M | $843.0M |
| Q4 25 | — | $9.0B | ||
| Q3 25 | — | $8.9B | ||
| Q2 25 | — | $8.0B | ||
| Q1 25 | — | $7.6B | ||
| Q4 24 | — | $7.6B | ||
| Q3 24 | — | $7.6B | ||
| Q2 24 | — | $7.6B | ||
| Q1 24 | $277.0K | $6.1B |
| Q4 25 | — | $9.7B | ||
| Q3 25 | $405.0M | $9.6B | ||
| Q2 25 | — | $9.5B | ||
| Q1 25 | — | $9.8B | ||
| Q4 24 | — | $10.3B | ||
| Q3 24 | $291.3M | $10.3B | ||
| Q2 24 | — | $9.8B | ||
| Q1 24 | $323.5M | $9.9B |
| Q4 25 | — | $19.6B | ||
| Q3 25 | $1.1B | $19.3B | ||
| Q2 25 | — | $18.3B | ||
| Q1 25 | — | $17.6B | ||
| Q4 24 | — | $18.2B | ||
| Q3 24 | $927.8M | $18.0B | ||
| Q2 24 | — | $17.7B | ||
| Q1 24 | $936.3M | $16.1B |
| Q4 25 | — | 0.92× | ||
| Q3 25 | — | 0.93× | ||
| Q2 25 | — | 0.84× | ||
| Q1 25 | — | 0.78× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | 0.74× | ||
| Q2 24 | — | 0.78× | ||
| Q1 24 | 0.00× | 0.62× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $216.6M | $827.1M |
| Free Cash FlowOCF − Capex | $210.7M | — |
| FCF MarginFCF / Revenue | 26.7% | — |
| Capex IntensityCapex / Revenue | 0.8% | — |
| Cash ConversionOCF / Net Profit | 1.56× | 3.86× |
| TTM Free Cash FlowTrailing 4 quarters | $359.6M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $827.1M | ||
| Q3 25 | $216.6M | $702.6M | ||
| Q2 25 | — | $364.0M | ||
| Q1 25 | — | $596.1M | ||
| Q4 24 | — | $742.5M | ||
| Q3 24 | $84.8M | $703.6M | ||
| Q2 24 | — | $658.2M | ||
| Q1 24 | $19.8M | $664.6M |
| Q4 25 | — | — | ||
| Q3 25 | $210.7M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $83.3M | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $18.1M | — |
| Q4 25 | — | — | ||
| Q3 25 | 26.7% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 37.2% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 8.9% | — |
| Q4 25 | — | — | ||
| Q3 25 | 0.8% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.7% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.9% | — |
| Q4 25 | — | 3.86× | ||
| Q3 25 | 1.56× | 2.44× | ||
| Q2 25 | — | 12.06× | ||
| Q1 25 | — | 2.50× | ||
| Q4 24 | — | 3.57× | ||
| Q3 24 | 2.57× | 1.29× | ||
| Q2 24 | — | 6.45× | ||
| Q1 24 | 0.56× | 139.10× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ATAT
Segment breakdown not available.
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
